Trial Profile
A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs AZD 2423 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 24 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jul 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 06 Jul 2011 Planned end date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.